Boundless Bio, Inc. BOLD
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- +100.00%
- 1 year
- +84.62%
- Market cap
- 55.65M
- EPS (ttm)
- -2.85
- Shares out
- 22.30M
- Forward P/E
- -0.70
- YTD return
- +100.00%
- 1-year return
- +84.62%
- Volume
- 138.91K
- Avg volume
- 169.54K
- Open
- 2.41
- Previous close
- 2.38
- Day's range
- 2.40 – 2.45
- 52-week range
- 0.961 – 3.16
- Analysts
- Buy
- Price target
- 14.50 (+504.2%)
- Earnings date
- Feb 6, 2025
2Y -0.47 (-16.15%)
Key statistics
- Enterprise value
- -109.26M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -35.86M
- Total cash
- 167.14M
- Total debt
- 121.00K
- Return on equity
- -41.16%
- Short % of float
- 1.05%
- 50-day average
- 2.91
- 200-day average
- 5.46
Analyst view
Consensus: buy
- Target (low)
- 14.00
- Target (mean)
- 14.50
- Target (high)
- 15.00
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 6, 2025
Expected Feb 6, 2025. Consensus EPS estimate -0.78333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 6, 2025 | Dec 1, 2024 | -0.74 | — | — | — |
| Nov 7, 2024 | Sep 1, 2024 | -0.76 | -0.74 | +0.02 | +2.63% |
| Aug 12, 2024 | Jun 1, 2024 | -0.78 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -0.78 | -0.77 | +0.01 | +1.28% |
| Feb 26, 2020 | Dec 1, 2019 | -1.02 | — | — | — |
| Nov 7, 2019 | Sep 1, 2019 | -1.07 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | Guggenheim | down | Buy | Neutral |
| Apr 22, 2024 | Leerink Partners | init | — | Outperform |
| Apr 22, 2024 | Guggenheim | init | — | Buy |
| Apr 22, 2024 | Piper Sandler | init | — | Overweight |
About Boundless Bio, Inc.
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- boundlessbio.com
News
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders? 
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders? 
Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency 
Callio Therapeutics Appoints Zachary Hornby As CEO 
Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer - Boundless Bio Q2 EPS $(1.06) Misses $(0.61) Estimate
Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders 
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? 
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD) 
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)
Your note
Sign in to keep a note on BOLD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARCH VENTURE FUND IX, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 1, 2024 | 0 |
| BUROW KRISTINA M | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 1, 2024 | 0 |
| CRANDELL KEITH L. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 1, 2024 | 0 |
| LIM JONATHAN E | Director | Conversion of Exercise of derivative security | Apr 1, 2024 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 1, 2024 | 0 |
| WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN I L | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 1, 2024 | 556,233 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.97% | 3,338,084 | 8.61M | Sep 29, 2024 |
| RA Capital Management, L.P. | 9.78% | 2,180,631 | 5.63M | Sep 29, 2024 |
| Nextech Invest Ag | 5.51% | 1,228,069 | 3.17M | Sep 29, 2024 |
| Redmile Group, LLC | 4.59% | 1,023,548 | 2.64M | Sep 29, 2024 |
| Wellington Management Group, LLP | 4.25% | 947,612 | 2.44M | Sep 29, 2024 |
| Citadel Advisors Llc | 3.22% | 718,527 | 1.85M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 1.31% | 291,755 | 752.73K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 0.87% | 194,911 | 502.87K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.83% | 185,641 | 478.95K | Oct 30, 2024 |
| Fidelity Growth Company K6 Fund | 0.41% | 92,210 | 237.90K | Oct 30, 2024 |
| Fidelity Series Growth Company Fund | 0.35% | 78,900 | 203.56K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.29% | 65,223 | 168.28K | Aug 30, 2024 |